Yes, an IUD can cause an infection, but the risk is concentrated in the first 20 days after insertion and in people who already carry gonorrhea or chlamydia at the time of placement. For most users, the absolute risk of a pelvic infection is low—roughly 0.5 to 2 percent in the weeks after insertion—and it drops sharply after the first month. The device itself does not "breed" bacteria; the risk comes from what gets pushed past the cervix during placement and from pre-existing sexually transmitted infections.
Mechanism: How Bacteria Reach the Upper Tract
The vagina and cervix are not sterile. They host a dense microbiome, and any object passed through the cervical canal can carry that flora upward. An IUD inserter crosses the cervical barrier, deposits the device in the uterine cavity, and withdraws. During that transit, vaginal and cervical bacteria can be introduced into the endometrium.
The uterine cavity is not equipped to handle a heavy bacterial load. Before insertion, the cervical mucus plug and the narrow cervical canal act as a gatekeeper. The inserter breaches that gate mechanically. Bacteria that were harmless in the vagina—such as anaerobic species and streptococci—can provoke inflammation when they reach the endometrium. This is why post-insertion infections, when they occur, tend to involve a mix of organisms rather than a single pathogen.
The more clinically significant pathway is pre-existing infection. Chlamydia trachomatis and Neisseria gonorrhoeae colonize the cervix and can ascend to the endometrium and fallopian tubes during insertion. If these organisms are present at the time the IUD is placed, the mechanical act of insertion can seed the upper tract. This is the core reason screening matters before placement.
A third mechanism involves the IUD string. The string passes through the cervix into the vagina, creating a continuous tract. Bacteria can theoretically travel along the string, but research has not shown this to be a major route of clinically significant infection in healthy users. The string is a conduit, not a pump.
Plain language: the IUD doesn't create bacteria—it can move bacteria that were already in the wrong place or carry them past the cervix's natural barrier.
Quantified Context: How Often Infection Actually Happens
The numbers here are reassuring for most users but need context. Large cohort studies and systematic reviews place the rate of pelvic inflammatory disease (PID) in the first 20 days after IUD insertion at roughly 0.5 to 2 percent. After the first month, the rate drops to a baseline that is similar to the background rate in people who do not use an IUD at all.
The landmark data come from studies of IUD users compared with non-users, which found the excess risk was almost entirely confined to the first three weeks. After that window, the incidence of PID in IUD users was comparable to the incidence in the general sexually active population. This is the single most important number in the entire discussion: the device does not create a persistent elevated infection risk for most users.
For comparison, the risk of PID after a single episode of untreated chlamydia is substantial—chlamydia is the leading infectious cause of PID, and untreated cervical infection can ascend in a meaningful fraction of cases. Screening and treating before insertion collapses the IUD-related risk into the same insertion-window risk that applies to any transcervical procedure.
Contextual comparisons help calibrate the number. The risk of serious infection from a single IUD insertion is lower than the risk of infection after many common outpatient procedures that breach a mucosal surface. The insertion-window PID rate is comparable to or lower than the rate of infection after surgical abortion, and lower than the rate of post-cesarean endometritis. These comparisons are not a reason for complacency; they are a reason to keep the risk in proportion.
Edge Cases: Who Faces a Higher Risk
Not every user carries the same background risk. Several subgroups warrant closer attention.
People with current or recent gonorrhea or chlamydia carry the highest risk. Insertion in the presence of an untreated cervical infection is the scenario most strongly associated with post-procedural PID. This is why current guidance from major bodies recommends screening for gonorrhea and chlamydia before IUD placement in people at risk, and treating before insertion when a test is positive.
People with a history of PID face a modestly higher baseline risk, though the evidence that a prior PID episode contraindicates IUD use is weak; most guidelines do not consider prior PID an absolute contraindication. The insertion-window risk still applies, and counseling should reflect that.
People with immunocompromise—including poorly controlled diabetes, HIV with low CD4 counts, or immunosuppressive therapy—have less robust defense against ascending infection. The mechanism is not different; the consequence is more severe. These users are not excluded from IUD use, but the risk-benefit conversation is more careful.
People with active cervicitis, unexplained vaginal bleeding, or a known pelvic infection should defer insertion until the acute process resolves. Placing a device into an infected cavity is the scenario that the insertion-window risk is designed to avoid.
Adolescents and young adults carry higher rates of chlamydia and gonorrhea than older users. Age alone is not a contraindication, but the higher background STI prevalence shifts the pre-insertion screening calculation. The excess risk in this group is driven by STI prevalence, not by the device.
Misconceptions: What the Evidence Does Not Support
Several persistent beliefs about IUDs and infection do not survive scrutiny.
The first is that the IUD itself acts as a chronic reservoir for bacteria. Studies comparing IUD users with non-users after the first month have not found a persistent elevation in PID risk. The device is not a nidus that continually seeds infection in a healthy user.
The second is that all IUDs carry the same risk profile. The evidence does not support a large difference in PID risk between copper and levonorgestrel-releasing IUDs. The mechanism—transcervical placement and pre-existing STI—applies to both. Product-specific differences in bleeding patterns are real; product-specific differences in PID risk are not well established.
The third is that a past IUD-related infection permanently rules out future IUD use. A treated infection with full resolution does not, by itself, preclude a subsequent IUD. The decision depends on the cause of the infection and the current risk profile.
The fourth is that the string must be cut very short to reduce infection. String length is not a proven driver of upper-tract infection. Short strings can make removal harder and are not recommended as an infection-control measure.
The fifth, and most clinically important, is the assumption that IUD use increases susceptibility to sexually transmitted infections. The evidence does not support a causal increase in STI acquisition attributable to the device. The risk is from the STI that is already present, not from the IUD making someone more likely to acquire one.
Timeline: When Symptoms Would Appear
| Time after insertion | What to watch for | Clinical meaning |
|---|---|---|
| 0 to 72 hours | Cramping, light bleeding | Expected post-insertion symptoms; not infection by themselves |
| 3 to 7 days | Fever, worsening pelvic pain, abnormal discharge | Concerning for early endometritis or PID; seek care |
| 7 to 20 days | Persistent pain, fever, pain with intercourse | Peak window for post-insertion PID |
| 20 days to 3 months | New fever, pelvic pain, discharge | Possible PID, though less directly tied to insertion |
| 3 months and beyond | New symptoms | Background risk comparable to non-users; evaluate on merits |
| Anytime | Fever above 101°F, severe pain, foul discharge | Red flag; same-day evaluation |
The timeline matters because the insertion-window pattern is the most actionable piece of information. Symptoms that appear within the first three weeks after placement deserve a lower threshold for evaluation than symptoms that appear months later.
Practical Actions: What to Do Before and After Insertion
The steps that reduce infection risk are concrete and well established.
Screen before insertion. For anyone at risk for gonorrhea or chlamydia, test and treat before the IUD is placed. This is the single highest-yield intervention. A negative test at the time of insertion collapses the STI-driven risk to near zero.
Treat before insertion when positive. If a test returns positive, complete treatment and confirm cure before placement. Placing a device into an untreated infected cervix is the avoidable scenario that drives most of the insertion-window risk.
Use the recommended insertion technique. Aseptic technique, single-use sterile equipment, and proper cervical preparation reduce the bacterial load introduced during placement. These are standard-of-care steps, not optional refinements.
Watch for red flags in the first three weeks. Seek same-day care for fever above 101°F, severe or worsening pelvic pain, pain with intercourse that is new and persistent, or abnormal vaginal discharge with odor. These symptoms are not proof of infection, but they warrant evaluation.
Do not remove the IUD on your own if symptoms appear. Removal without treating an underlying infection can leave the infection unaddressed. Evaluation comes first.
Reconcile the thresholds. The 0.5 to 2 percent figure refers to PID in the first 20 days. The 101°F threshold is a fever cutoff that warrants evaluation, not a diagnostic criterion. The three-week window is the period of elevated risk, not a deadline after which symptoms can be ignored. These numbers serve different purposes: one describes population risk, one describes a clinical trigger, and one describes a time course.
Limitations: What the Evidence Cannot Tell You
The evidence base has real gaps. Much of the PID risk data comes from older cohort studies conducted before routine chlamydia screening and before modern insertion technique became standard. The absolute rates in current practice may be lower than the historical figures, and the true current rate is difficult to pin down without contemporary large-scale surveillance.
The evidence also cannot give a precise individualized risk for any single user. The population rates are averages across heterogeneous groups. A user with no STI risk factors and a user with a recent untreated chlamydia infection face very different absolute risks, even though both fall under the same broad "IUD user" label.
Finally, the evidence does not support strong claims about rare infectious complications beyond PID. The data on tubo-ovarian abscess in IUD users is limited to case series, and the incidence is low enough that precise rates are not well established. The mechanism is plausible; the frequency is not precisely quantified.
What can be said with confidence is this: the infection risk from an IUD is real, it is concentrated in a narrow window, and it is largely modifiable through pre-insertion screening and prompt evaluation of symptoms. The device is not the enemy; the bacteria that were already there are.